Tag Archive for: radiopharmaceutical

Lu 177-dotatate (pink and orange) binds to somatostatin receptors (green) on neuroendocrine tumor cells (blue) and kills the cells through the release of radioactive particles.@ NCI. Credit: Adapted from Frontiers in Oncology. January 2019. Front. Oncol. doi: 10.3389/fonc.201800663
radiopharmaceutical

ITM gets equity to launch Phase III lead radiopharmaceutical ITM-11

ITM Isotope Technologies Munich SE has raised €188m ito boost radiopharma pipeline, contract manufacturing cpacity, and launch ITM-11.

Read more
Canadian Fusion Therapeutics Inc is utilising the advantages of alpha medical isotopes to develop targeted alpha therapies. The company uses targeting molecules, such as antibodies, armed with potent alpha emitting isotopes to precisely and effectively induce cancer cell death by induction of DNA double strand breaks. © Fusion Therapeutics Inc
acquisition

AstraZeneca to take over Fusion Therapeutics Inc

British pharma giant AstraZeneca has announced to acquire radio-conjugate specialist Fusion Therapeutics Inc for US$2bn upfront.

Read more
Seat of Orbit Discovery © Orbit Discovery
radiopharmaceutical

Radiotherapy R&D partnership

Orano Med SAS and Orbit Discovery Ltd announced a collaboration to develop Peptide Receptor Radionuclide Therapies for cancer cells and develop novel radiopharmaceuticals.

Read more